Rare diseases contribute to revenue
Photo: Fredrik Sandberg/TT

Rare diseases contribute to revenue lift for AstraZeneca

Pharmaceutical group AstraZeneca reiterates its revenue forecast for 2026. The company said this in connection with its interim first-quarter figures.

Advertisement

The company's revenue rose eight percent during the quarter, to almost $15.3 billion, primarily driven by growth in oncology and rare diseases, the company said.

This comes at the same time that the operating profit for the company's core business increased by twelve percent.

“We continue to invest in our commercial capabilities as we prepare for multiple launches, look forward to further results expected throughout the year, and remain on track to achieve our ambition for 2030 and beyond,” CEO Pascal Soriot said in the report.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All